| Literature DB >> 25087755 |
Jangsup Moon1, Soon-Tae Lee1, Jung-Won Shin1, Jung-Ick Byun1, Jung-Ah Lim1, Yong-Won Shin1, Tae-Joon Kim1, Keon-Joo Lee1, Kyung-Il Park2, Keun-Hwa Jung1, Ki-Young Jung1, Sang Kun Lee1, Kon Chu3.
Abstract
Amphiphysin antibody causes paraneoplastic stiff-person syndrome and can also result in a variety of neurological manifestations. Here, we investigated the clinical spectrum of 20 patients with non-stiff anti-amphiphysin syndrome and their responses to immunotherapy. The most common neurological manifestation was limbic encephalitis (n=10), followed by dysautonomia (n=9), and cerebellar dysfunction (n=6). Cancer was detected in only seven patients. Intravenous immunoglobulin or steroid treatment was effective in most patients, but three improved only after rituximab treatment. Our study suggests that anti-amphiphysin syndrome can manifest as non-stiff encephalomyelitis and is only partially associated with cancer. Active immunotherapy, including rituximab, would be beneficial.Entities:
Keywords: Anti-amphiphysin antibody; Immunotherapy; Paraneoplastic neurological syndrome; Stiff-person syndrome; rituximab
Mesh:
Substances:
Year: 2014 PMID: 25087755 DOI: 10.1016/j.jneuroim.2014.07.011
Source DB: PubMed Journal: J Neuroimmunol ISSN: 0165-5728 Impact factor: 3.478